- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01142115
Test of Discomfort and Malaise of Two Different Urine Catheters in Healthy Volunteers
Comparative Study of Two Different Urine Catheters.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Intermittent catheterization is the preferred method for emptying the bladder in patients with spinal cord injury and neurogenic bladder dysfunction.
Coloplast has developed a new intermittent catheter. In this investigation this new test catheter will be compared with SpeediCath by assessing discomfort and pain associated with catheterization of healthy men. The reason for choosing healthy men is that many catheter users do not have full feeling in their urethra and therefore can not assess the discomfort.
Healthy men who are ≥ 18 years and have no signs of urinary tract infection and do not have abnormalities, disease or have had operational interventions in the urinary tract will be included. They are recruited through advertisements on the website www.forsoegsperson.dk.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Copenhagen, Danmark, 2100
- Rigshospitalet, dep. 2112
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- 18 years or older
- Male
- signed informed Consent,
- Neg. urine multistix
Exclusion Criteria:
- Abnormalities,
- diseases or surgical procedures performed in the lower urinary-tract
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Monza
nonCE marked intermittent catheter
|
intermittent catheterisation
Andre navn:
|
|
Aktiv komparator: control
SpeediCath coated catheter
|
intermittent catheterisation
Andre navn:
intermittent catheterisation
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Discomfort Measured on the Visual Analog Scale (VAS)
Tidsramme: 10 minutes after each catheterisation at visit 1 and at visit 2 which is 5-25 days after visit 1
|
Outcome measured on a 10 cm Visual Analog Scale ranging from "no discomfort" (0cm) to "worst thinkable discomfort" (10cm).
|
10 minutes after each catheterisation at visit 1 and at visit 2 which is 5-25 days after visit 1
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Irritation During Voiding After Catheterization
Tidsramme: 10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
|
After each catheterization subjects were asked if they felt any irritation during voiding with answer option yes or no. Yes - they experienced irritation. No - they did not experience irritation. |
10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
|
|
Ease of Use Measured on a 5 Point Scale: Insertion Effort
Tidsramme: 10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
|
After each catheterization the nurse who conducted the catheterization answered how the catheter insertion had been. There were 5 answer categories: very difficult - difficult - neither easy nor difficult - easy - very easy |
10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
|
|
Ease of Use Measured on a 5 Point Scale: Withdrawal Effort
Tidsramme: 10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
|
After each catheterization the nurse who conducted the catheterization answered how the catheter withdrawal had been. There were 5 answer categories: very difficult - difficult - neither easy nor difficult - easy - very easy |
10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
|
|
Visible Blood
Tidsramme: 10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
|
Visual blood observed on the catheter or in the urine in connection to catheterization. The nurse who conducted the catheterization could answer yes or no as follows: Yes = visible blood observed. No = no visible blood observed. |
10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
|
|
Haematuria
Tidsramme: 2 hours after catheterisation at visits 1 and 2
|
Negative or positive result on a multistix urin analysis. Negative haematuria: 10 erythrocytes/microliter or less. Positive haematuria: above 10 erythrocytes/microliter. |
2 hours after catheterisation at visits 1 and 2
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Rikke Otttesen, CTM, Coloplast A/S
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CP063CC
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Ryggmargs-skade
-
ARCAGY/ GINECO GROUPRoche Pharma AGFullført
-
Seoul National University HospitalFullførtNevrogen blære | Tethered Spinal Cord Syndrome
-
Herlev and Gentofte HospitalRekruttering
-
Centre Hospitalier de ColmarRekruttering
-
Hospital Universitari Son DuretaEspen; This research prize was funded by Nestle Nutrition Institute and...FullførtModerat til alvorlig traume, som definert av en | Injury Severity Score (ISS) > 12 poeng ble inkludert i studien.Spania
-
Kourosh AfsharHar ikke rekruttert ennåSunn | TestikkeltorsjonCanada
-
Sheffield Children's NHS Foundation TrustRekrutteringTorsjon Testis | Pungen sykdomStorbritannia
-
Ying JiangHar ikke rekruttert ennåEpididymitt | Testikkeltorsjon | Testikulær appendiks torsjonKina
-
University Hospital, LinkoepingLinkoeping UniversityRekrutteringAkutt pungen | Testikkeltorsjon | Scrotal smerteSverige
Kliniske studier på Intermittent catheter CP063CC
-
Poitiers University HospitalHar ikke rekruttert ennåFriske Frivillige | Intermitterende hypoksiFrankrike
-
Moscow Scientific and Practical Center of Medical...Har ikke rekruttert ennåIskemisk hjerneslag | Øvre ekstremitets motoriske nedsatt funksjonRussland
-
Spaulding Rehabilitation HospitalFoundation Wings For LifeAktiv, ikke rekrutterende
-
Vastra Gotaland RegionRekruttering
-
Inogen Inc.Har ikke rekruttert ennå
-
Xijing HospitalHar ikke rekruttert ennåEnteral ernæring | Alvorlig hjerneslag
-
Mansoura UniversityHar ikke rekruttert ennåNedre urinveissymptomer | ProstataobstruksjonEgypt
-
Douglas Mental Health University InstituteCentre de recherche CERVO; Centre de Recherche de l'Institut Universitaire... og andre samarbeidspartnereRekrutteringSchizofreni og predominante negative symptomerCanada
-
University of FloridaRekrutteringKognitiv svekkelse etter deliriumForente stater
-
Cairo UniversityHar ikke rekruttert ennå